Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial

J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):489-93. doi: 10.1097/QAI.0b013e31824bb720.

Abstract

Among 103 patients with multidrug-resistant HIV who initiated raltegravir, etravirine, and darunavir/ritonavir-containing regimen in the ANRS 139 TRIO trial, 100 participated in extended follow-up and continued study treatment until week 96. Among them, 87 (87%) received an optimized background therapy including either nucleoside reverse transcriptase inhibitors or enfuvirtide, they were 78 (78%) at week 96. At week 96, 88% achieved durable virologic response (<50 copies/mL). CD4 response was maintained (median change of +150 cells/mm(3)). No major toxicity was reported. This triple drug combination showed sustained efficacy and thus should be strongly considered for patients with multiclass-resistant virus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Darunavir
  • Drug Resistance, Multiple, Viral / drug effects
  • Drug Resistance, Multiple, Viral / genetics
  • Female
  • Follow-Up Studies
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • HIV Protease Inhibitors / adverse effects
  • HIV Protease Inhibitors / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Nitriles
  • Pyridazines / administration & dosage
  • Pyridazines / adverse effects
  • Pyrimidines
  • Pyrrolidinones / administration & dosage
  • Pyrrolidinones / adverse effects
  • RNA, Viral / analysis
  • Raltegravir Potassium
  • Ritonavir / administration & dosage
  • Ritonavir / adverse effects
  • Sulfonamides / administration & dosage
  • Sulfonamides / adverse effects

Substances

  • HIV Protease Inhibitors
  • Nitriles
  • Pyridazines
  • Pyrimidines
  • Pyrrolidinones
  • RNA, Viral
  • Sulfonamides
  • etravirine
  • Raltegravir Potassium
  • Ritonavir
  • Darunavir